Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Bioepis’ Adalimumab Has A Longer Life Out Of The Fridge

Executive Summary

Samsung Bioepis’ Imraldi adalimumab biosimilar has been granted a European label update that approves the product to be stored in non-refrigerated conditions for up to 28 days.

You may also be interested in...

Samsung Bioepis’ Ko Insists On Value Of Data

In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.

Attracting 60,000 Adalimumab Patients Aids Biogen

Rolling out its Imraldi adalimumab brand across Europe is maintaining growth in Biogen’s biosimilars franchise as sales of its Benepali etanercept drug slip back.

Samsung Bioepis Targets Brazil With Brenzys

Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.

Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts